Globus Medical Stock (NYSE:GMED)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$86.65

52W Range

$51.79 - $101.40

50D Avg

$90.71

200D Avg

$71.47

Market Cap

$11.79B

Avg Vol (3M)

$1.33M

Beta

1.07

Div Yield

-

GMED Company Profile


Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

5,300

IPO Date

Aug 03, 2012

Website

GMED Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Emerging Technology$154.00M$120.22M$96.14M
Spine$2.37B$1.45B$926.70M

Fiscal year ends in Dec 25 | Currency in USD

GMED Financial Summary


Dec 25Dec 24Dec 23
Revenue$2.94B$2.52B$1.57B
Operating Income$479.82M$165.99M$133.14M
Net Income$537.87M$102.98M$122.87M
EBITDA$479.82M$473.73M$346.58M
Basic EPS$3.98$0.76$1.09
Diluted EPS$3.92$0.75$1.07

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 24, 26 | 4:30 PM
Q3 25Nov 06, 25 | 4:30 PM
Q2 25Aug 08, 25 | 4:30 PM

Peer Comparison


TickerCompany
PENPenumbra, Inc.
ATRAptarGroup, Inc.
BIOBio-Rad Laboratories, Inc.
MOHMolina Healthcare, Inc.
DVADaVita Inc.
GRFSGrifols, S.A.
HQYHealthEquity, Inc.
ALGNAlign Technology, Inc.
HSICHenry Schein, Inc.